Genitourinary Drugs: Technologies and Global Markets

Report Code: PHM115A

Publish Date: Jun 2012

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The total market for genitourinary drugs is projected to increase from $26.5 billion in 2011 to $30.7 billion in 2016 at a compound annual growth rate (CAGR) of 3% for a period of five years, from 2011 to 2016.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period (2011 to 2016) are discussed.  New product launches will be discussed.  Revenue figures for 2010 are in an actual figure, except where actual results have not been reported due to the release timing of the report.

The report includes analysis of leading and emerging drug products for each genitourinary disease.  Profiles of manufacturers of leading products and their specific products are provided.  This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.  The competitive environment is examined with a special focus on how new products will alter the quality of life of patients with genitourinary diseases.

Market figures are based on revenues at the manufacturers’ level and are projected at 2011-dollar value.  Inflation is not computed into the projection figures.  Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market

Included in this report are forecasts by product, product category and company from 2009 through 2016.  The study is arranged to offer an overview of the genitourinary disease drug market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country.  Virtually the entire globe is covered to include prevalence data for each drug subsegment.

Where possible, epidemiological data is presented to underscore the importance of these diseases in the world population and the potential morbidity/mortality resulting from ineffective treatment of these diseases worldwide.  Patent and clinical trial information is reviewed for various drugs.  The status of approvals of drugs in each disease segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change.  Revenue figures do not account for variation in local currencies.

Diagnostics for each disease area and various drugs are described.  However, diagnostics are not included in market figures, as they are outside of the scope of this report.

All market share data presented is on a global basis, unless specifically noted.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Genitourinary Drugs: Technologies and Global Markets198Free
Chapter- 1: INTRODUCTION5Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW10Free
Chapter- 4: GENITOURINARY DISEASE CONDITIONS20Free
Chapter- 5: MARKET ANALYSIS7Free
Chapter- 6: BENIGN PROSTATIC HYPERTROPHY (BPH)31Free
Chapter- 7: ERECTILE DYSFUNCTION20Free
Chapter- 8: URINARY INCONTINENCE AND OVERACTIVE BLADDER26Free
Chapter- 9: INFERTILITY18Free
Chapter- 10: HORMONAL CONTRACEPTION17Free
Chapter- 11: GENITOURINARY INFECTION4Free
Chapter- 12: GLOBAL GENITOURINARY DISEASE DRUG MARKET7Free
Chapter- 13: PATENT EXAMPLES FOR GENITOURINARY DRUGS2Free
Chapter- 14: C. CRAMER & CO. GMBH28Free

Related Reports

Markets for Emerging Pharmaceutical Technologies

Published - Mar 2011 | Publisher - Jackson Highsmith | Code - PHM100A

As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR) of 10.6%.

Emerging Regional Markets for Therapeutic Drugs

Published - Feb 2011 | Publisher - Jackson Highsmith | Code - PHM076A

The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015.

Biologic Therapeutic Drugs: Technologies and Global Markets

Published - Jan 2011 | Publisher - Jackson Highsmith | Code - BIO079A

The global biologics market is valued at an estimated $149 billion in 2010 and is expected to reach $239 billion by 2015, a compound annual growth rate (CAGR) of 9.9% from 2010-2015. Driving this growth is the need for a more extensive drug pipeline, attractive targets against challenging diseases, a push to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.

Recent Reports

Active Pharmaceutical Ingredients: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM200C

The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.

Global Market for Contract Research Organization (CRO) Services

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM186C

The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Global Oncology Pharmaceuticals Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM256B

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

Excipients in Pharmaceuticals: Global Markets to 2029

Published - Sep 2024 | Publisher - Gundreddy Gopinadh | Code - PHM010M

The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.

Antibody-Drug Conjugates: Technologies and Global Markets

Published - Sep 2024 | Publisher - BCC Publishing | Code - PHM161C

The global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to reach $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Genitourinary Drugs: Technologies and Global Markets
Customize Report